| Date | Title | Description |
| 27.03.2026 | European Deep Tech Attracts Mega Capital: AI, Robotics, Biotech, and Climate Solutions Secure Major Funding | European startups attract massive capital. Kandou AI leads with $225 million for AI infrastructure connectivity, breaking memory bottlenecks. Interloom secured $16.5 million for business automation software. Kewazo raised $15 million to rev... |
| 25.03.2026 | Kandou AI bekommt 225 Millionen – Interloom sammelt 16,5 Millionen ein – Kewazo streicht 15 Millionen ein | Im #DealMonitor für den 25. März werfen wir einen Blick auf die wichtigsten, spannendsten und interessantesten Investments und Exits des Tages in der DACH-Region. Alle Deals der Vortage gibt es im großen und übersichtlichen #DealMonitor-Arc... |
| 23.03.2026 | Robotics Revolutionizes Heavy Industry: KEWAZO Secures $35 Million to Accelerate Automation | KEWAZO secured $35 million. It pioneers heavy industry automation. Its LIFTBOT robot replaces manual lifting. It operates at over 20 global sites. This boosts safety, efficiency, and project schedules. The funding fuels expanded deployments... |
| 22.03.2026 | KEWAZO: $35 Million Raised To Scale Heavy-Industry Robotics And AI Platform | KEWAZO, a Munich and Houston-based robotics and AI company focused on automating heavy industry, announced it has secured new funding that brings its total capital raised to $35 million. The round was led by Schooner Capital and included pa... |
| 19.03.2026 | Kewazo Closes Series A Extension Funding | Kewazo, a Munich, Germany- and Houston, TX-based robotics company, raised a Series A extension funding.
The round, reportedly a Series A extension amounting to $16m, was led by Schooner Capital with participation from Chevron Technology Ven... |
| 14.01.2026 | Caldera Therapeutics Launches with $112.5M in Total Capital | Caldera Therapeutics, Inc., a Cambridge, MA-based clinical stage biotechnology company, launched with $112.5M total capital raised.
The amount consisted of a $75M Series A round from Atlas Venture, LAV and venBio, and most recently a $37.5M... |
| 14.01.2026 | Caldera Therapeutics Launches With $112.5 Million And Doses First Subjects In Phase 1 Trial Of CLD-423 | Caldera Therapeutics, a clinical-stage biotechnology company developing a first-in-class bispecific antibody for inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases, launched with $112.5 million in total capital... |
| 13.01.2026 | Kinaset Therapeutics Secures $103M for Severe Asthma Drug Advancement | Kinaset Therapeutics obtained $103 million in Series B funding. This capital fuels the development of frevecitinib. Frevecitinib is an innovative inhaled pan-JAK inhibitor. It targets severe asthma and other serious respiratory diseases. Th... |
| 12.01.2026 | EQT Life Sciences backs Kinaset Therapeutics’ USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases | EQT Life Sciences backs Kinaset Therapeutics’ USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases
Mon, Jan 12, 2026 13:00 CET Report this content
EQT Life Sciences invests in U.S.-based Kinaset Thera... |
| 12.01.2026 | Kinaset Therapeutics Raises $103M in Series B Funding | Kinaset Therapeutics, a Boston, MA-based clinical-stage biopharmaceutical company, raised $103M in Series B funding.
The round was led by RA Capital Management and Forge Life Science Partners, with participation from new investors EQT Life ... |
| 11.01.2026 | Diagonal Therapeutics Secures $125M to Propel Innovative Antibody Therapies | Diagonal Therapeutics secured $125M Series B funding. This advances DIAG723, a first-in-class clustering antibody. It targets hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH). The Watertown biotech corre... |
| 11.01.2026 | Diagonal Therapeutics: $125 Million Series B Raised To Advance DIAG723 Clustering Antibody Into the Clinic | Diagonal Therapeutics announced it has raised $125 million in an oversubscribed Series B financing to advance its lead program, DIAG723, a first-in-class “clustering antibody” designed to correct dysregulated receptor signaling implicated i... |
| 10.01.2026 | Kinaset Therapeutics: $103 Million Series B Closed To Advance Inhaled Pan-JAK Drug For Severe Asthma | Kinaset Therapeutics, a clinical-stage biopharmaceutical company focused on developing inhaled therapies for severe respiratory diseases, announced it has closed a $103 million oversubscribed Series B financing to fund mid-stage development... |
| 09.01.2026 | Diagonal Therapeutics Raises $125M in Series B Financing | Diagonal Therapeutics, a Watertown, MA-based biotechnology company developing disease-modifying clustering antibodies that correct dysregulated signaling in severe genetic diseases, raised $125M in Series B Funding.
The round was co-led by ... |
| 15.12.2025 | DISCO Pharmaceuticals: €36 Million Seed Funding Raised And Mark Manfredi Named As CEO | DISCO Pharmaceuticals has appointed biotech executive Mark Manfredi, Ph.D., as chief executive officer and completed the final close of a €36 million seed financing round to advance its pipeline of surfaceome-targeted drug candidates for ha... |
| 11.12.2025 | Triana Biomedicines: $120 Million Series B Secured To Advance Molecular Glue Degrader Pipeline | Triana Biomedicines has closed an oversubscribed $120 million Series B financing round that will accelerate development of its molecular glue degrader platform and advance its lead program, TRI-611, toward clinical proof-of-concept in patie... |
| 08.11.2025 | AAVantgarde Secures $141M for Groundbreaking Gene Therapies | AAVantgarde Bio closed a $141 million Series B round. This substantial funding propels gene therapy programs for inherited retinal diseases. Key targets: Stargardt disease and Usher Syndrome Type 1B. Both represent severe conditions with no... |
| 07.11.2025 | Autonomous Security Drones Soar: Sunflower Labs Secures $16M, Gains Full FAA BVLOS Approval | Sunflower Labs secured $16M Series B funding, led by Sequoia Capital. The company also achieved nationwide FAA approval for Beyond Visual Line of Sight (BVLOS) drone operations. A new interactive property configuration tool launched. The Be... |
| 07.11.2025 | AAVantgarde: $141 Million Series B Closed To Advance Clinical Programs For Stargardt Disease And Usher 1B Syndrome | AAVantgarde Bio has closed a $141 million (€122 million) Series B financing to advance its lead clinical programs targeting inherited retinal diseases. The financing round was co-led by Schroders Capital, Atlas Venture, and Forbion, with pa... |
| 06.11.2025 | AAVantgarde Closes $141M Series B Financing | AAVantgarde Bio, a Milan, Italy-based clinical-stage, biotechnology company developing therapies for inherited retinal diseases (IRDs), raised $141M in Series B funding.
The round was led by Schroders Capital, as well as existing investors ... |
| 04.11.2025 | Sunflower Labs Closes $16M Series B Funding | Sunflower Labs, the San Carlos, CA-based creator of the Beehive autonomous security drone system, closed a $16m Series B funding round.
The round was led by Sequoia Capital with participation from Alarm.com, DRONE FUND, Gentian Investments,... |
| 17.10.2025 | Affinia Therapeutics: $40 Million Series C Raised For Advancing Gene Therapies For Cardiovascular And Neurological Diseases | Affinia Therapeutics, a biotechnology company pioneering engineered adeno-associated virus (AAV) gene therapies for severe cardiovascular and neurological conditions, has announced the closing of a $40 million Series C financing round. The ... |
| 08.10.2025 | Affinia Therapeutics Raises $40M in Series C Financing | Affinia Therapeutics, a Waltham, MA-based gene therapy company with a pipeline of first-in-class and/or adeno-associated virus (AAV) gene therapies for devastating cardiovascular and neurological diseases, raised $40M in Series C financing.... |
| 08.09.2025 | Atlas Venture: $400 Million Opportunity Fund III Closed For Supporting Biotech Innovation | Atlas Venture has announced the closing of its third Opportunity Fund, securing $400 million in an oversubscribed round. This latest fund, known as Opportunity Fund III, marks a significant milestone in Atlas’s continued evolution as a lead... |
| 05.09.2025 | Atlas Venture closes on $400m Opportunity Fund III | - |
| 10.07.2025 | Renasant Bio Raises $54.5M in Seed Funding | Renasant Bio, a Berkeley, CA-based developer of disease-modifying treatments for autosomal dominant polycystic kidney disease (ADPKD), raised $54.5M in Seed funding.
The round was led by 5AM Ventures, alongside other life sciences investors... |
| 15.01.2025 | Be Bio Closes $92M Series C Financing | Be Bio, a Cambridge, MA-based company which specializes in B Cell Medicines (BCMs), raised $92M in Series C funding.
The round was led by Nextech with existing investors including ARCH Venture Partners, Atlas Venture, RA Capital Management,... |
| 14.12.2024 | The Rise of nChroma Bio: A New Dawn in Genetic Medicine | In the world of biotechnology, mergers and funding are the lifeblood of innovation. Recently, two companies, Chroma Medicine and Nvelop Therapeutics, joined forces to create nChroma Bio. This new entity is set to redefine the landscape of g... |
| 12.12.2024 | Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio and Raises $75M | Biotechnology companies Chroma Medicine (Boston, MA) and Nvelop Therapeutics (Cambridge, MA) announced their merger and subsequent launch of nChroma Bio to expand the R&D of the genetic medicines sector.
Concurrent with the merger, nChr... |
| 08.12.2024 | Atlas Venture: $450 Million Fund XIV Closed To Invest In Biotech Innovation | Atlas Venture—a leading early-stage venture capital firm investing in biotech innovation—announced closing its fourteenth fund, raising $450 million in an oversubscribed fundraise. Through Fund XIV, Atlas Venture will continue collaborating... |
| 13.11.2024 | Trace Neuroscience: A New Dawn in Genomic Medicine for ALS | In the realm of biopharmaceuticals, a new player has emerged, armed with ambition and a hefty $101 million in Series A funding. Trace Neuroscience is on a mission to reshape the landscape of genomic medicine, particularly for those grapplin... |
| 13.11.2024 | Trace Neuroscience: $101 Million (Series A) Raised To Expand Genomic Medicine Platform | Trace Neuroscience – a biopharmaceutical company expanding the promise of genomic medicine for people living with neurodegenerative diseases – announced its launch with a $101 million Series A funding led by Third Rock Ventures, with partic... |
| 28.10.2024 | Be Biopharma: Pioneering the Future of Genetic Medicine with $82 Million in New Funding | In the ever-evolving landscape of biotechnology, Be Biopharma stands out like a lighthouse in a storm. This Cambridge, Massachusetts-based company has just secured $82 million in funding, a financial windfall that promises to propel its inn... |
| 25.10.2024 | Be Bio: $82 Million Raised To Discover And Develop Engineered B Cell Medicines | Be Biopharma – a leader in the discovery and development of engineered B Cell Medicines (BCMs) – announced key milestones alongside a new round of funding as its lead program BE-101 for Hemophilia B, enters the clinic, and its second develo... |
| 07.10.2024 | Kailera Therapeutics: $400 Million (Series A) Raised To Advance Next-Gen Therapies For Obesity | Kailera Therapeutics announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for treating obesity and related conditions. And Kailera launches with a $400 million... |
| 04.10.2024 | Triveni Bio: $115 Million (Series B) Closed To Advance Novel Antibody Treatments For I&I Disorders | Triveni Bio, a biotech company advancing novel antibody treatments for I&I disorders, announced a $115 million Series B to support pipeline expansion. The funding round was led by Goldman Sachs Alternatives with significant participatio... |
| 30.07.2024 | BioIVT Appoints Dr. Judith Dunn and Dr. Auro Nair to its Board of Directors | WESTBURY, N.Y., July 30, 2024 /PRNewswire/ -- BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced the appointment of Dr. Judith Dunn and Dr. Auro Nair to its Board of Dir... |
| 29.07.2024 | Scorpion Therapeutics: A Bold Leap in Precision Oncology | Scorpion Therapeutics is making waves in the world of cancer treatment. With a recent $150 million Series C funding round, the Boston-based biotech is poised to redefine the landscape of precision oncology. This funding is not just a financ... |
| 27.07.2024 | Scorpion Therapeutics Raises $150 Million For Enhancing Clinical-Stage Precision Oncology Pipeline | Scorpion Therapeutics, a clinical-stage oncology company dedicated to transforming the lives of cancer patients by redefining the frontier of precision oncology, announced the closing of a $150 million Series C financing. The funding was co... |
| 25.07.2024 | GRO Biosciences Secures $60 Million to Revolutionize Gout Treatment**
** | ** In the bustling world of biotechnology, innovation is the lifeblood. GRO Biosciences, or GRObio, has just taken a giant leap forward. The company recently announced the closing of an oversubscribed $60.3 million Series B financing round.... |
| 19.07.2024 | GRO Biosciences Closes $60M Series B Financing Co-Led by Atlas Venture and Access Biotechnology | Proceeds to advance clinical development of lead program for gout, broaden the Company’s pipeline, and expand its genomically recoded organism platform
BOSTON–(BUSINESS WIRE)–July 19, 2024–
GRO Biosciences Inc. (“GRObio”), a biotechnology c... |
| 19.07.2024 | GRO Biosciences: Protein Therapeutics Company Raises $60 Million In Series B | GRO Biosciences (GRObio), a biotechnology company leveraging synthetic biology to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the closing of an oversubscribed $60.3 million Series B fin... |
| 02.05.2024 | Forbion Portfolio Company Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer | • Latest deal marks the fifth Forbion portfolio company to be acquired for over $1 bn within a year
Naarden, The Netherlands, 2 May 2024 - Forbion portfolio company Mariana Oncology (Mariana) is to be acquired by Novartis for $1 billion in ... |
| 23.10.2023 | Which VCs are investing in rare diseases? | Firms include Chiesi Ventures, Frazier Healthcare Partners, OrbiMed, and Atlas Venture
In the United States alone 25 million people suffer from rare disease, a number that jumps to 400 million people globally. While 1 in 10 people will suff... |
| 23.10.2023 | Ai Build raises $8.5 million to expand the use of AI in additive manufacturing | London-based 3D printing software developer Ai Build has raised $8.5 million in a Series A funding round.
This funding will be used to accelerate Ai Build’s product roadmap and provide more industrial 3D printing customers with increased au... |
| 11.08.2022 | AbCellera Partners With Atlas Venture to Discover Therapeutic Antibodies | Vancouver, BC-based AbCellera (Nasdaq: ABCL) and Atlas Venture, a Cambridge, MA-based biotech venture capital firm, announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed a... |
| 03.03.2022 | Atlas Venture Raises $450 Million Fund XIII | Atlas Venture, a Cambridge, Mass.-based early stage venture capital firm investing in biotech innovation, closed its thirteenth fund, at $450 million.
With Fund XIII, Atlas Venture will continue working alongside talented entrepreneurs to c... |
| 31.01.2022 | Equity Alliance, Investor in Minority- and Female-Led Venture Funds, Raises $28.6 Million | Equity Alliance, a new firm backed by boldface names in business and venture capital, has closed a $28.6 million fund to invest in venture funds led by women and minority managers.
While the firm is focused on returns, it also aims to provi... |
| 14.10.2021 | Rectify Pharmaceuticals Launches with $100 Million Series A Financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund | Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics that restore ABC transporter function, today announced it has closed a $100 million Series A... |
| 01.10.2021 | StartUPDATES: New developments for healthcare startups | HealthMine‘s EVP of Consulting and Professional Services, Melissa Smith, recently led a presentation sharing how health plans can shift their member engagement strategy to effectively reach members post-pandemic. Check it out to learn how d... |
| 01.10.2021 | Atlas Venture Closes $300M Second Opportunity Fund | Atlas Venture, a Cambridge, Mass.-based early stage venture capital and venture creation firm investing in biotech innovation, closed its second Opportunity Fund, at $300m.
Led by David Grayzel, Kevin Bitterman, Bruce Booth, Jean-François F... |
| 14.07.2021 | Jodie Morrison Joins Atlas Venture as Venture Partner | Atlas Venture, a Cambridge, MA-based early stage venture capital firm, hired Jodie Morrison as a venture partner.
Morrison will work with the Atlas team to build transformative new biotech companies.
Morrison is an executive and board membe... |
| 14.07.2021 | Atlas : Seaspan Completes Significantly Upsized $750 Million Offering of Blue Transition Bonds | Marks Inaugural Entry into US Unsecured Market
LONDON, July 14, 2021 /PRNewswire/ - Seaspan Corporation ("Seaspan"), a wholly owned subsidiary of Atlas Corp. ("Atlas") (NYSE: ATCO), today announced that it has successful... |
| 09.07.2021 | Atlas : Seaspan Announces Pricing of Upsized $750 Million 5.50% Senior Unsecured Blue Transition Bonds | LONDON, UK, July 9, 2021 /CNW/ - Seaspan Corporation ("Seaspan"), a wholly owned subsidiary of Atlas Corp. ("Atlas") (NYSE: ATCO), today announced that it priced an offering (the "Offering") of $750 million agg... |
| 06.07.2021 | Atlas : Seaspan Announces $500 Million Offering of Senior Unsecured Blue Transition Bonds | LONDON, July 6, 2021 /PRNewswire/ - Seaspan Corporation ("Seaspan"), a wholly owned subsidiary of Atlas Corp. ("Atlas") (NYSE: ATCO), today announced that it intends to offer, subject to market conditions and other facto... |
| 28.05.2021 | ATLAS CORP.
Atlas : Announces Significant Enhancements and Total Capacity Increase to its Industry-Leading Innovative $2.5 billion Portfolio Financing Program (Form 6-K) | Announces Significant Enhancements and Total Capacity Increase to its Industry-Leading
Innovative $2.5 billion Portfolio Financing Program
London, UK, May 24, 2021 - Seaspan Corporation ('Seaspan'), a wholly owned subsidiary of Atlas Corp. ... |
| 24.05.2021 | ATLAS CORP.
Atlas : Seaspan Announces Completion of the Largest Reported Sustainability-Linked US Private Placement of $500 million as part of its Amended & Upsized $2.5 billion Portfolio Financi... | Announces Significant Enhancements and Total Capacity Increase to its Industry-Leading
Innovative $2.5 billion Portfolio Financing Program
LONDON, May 24, 2021 /CNW/ - Seaspan Corporation ("Seaspan"), a wholly owned subsidiary of ... |
| 05.04.2021 | Swiggy announces $800 million fund raise through global venture funds, investors | Image: Wikimeda Commons
Food delivery app Swiggy has raised $800 million in a new round of funding that will value it at $5 billion.
The round saw participation from global alternative asset manager Falcon Edge Capital, Singapore-based fund... |
| 17.02.2021 | Boreal Ventures launches $26 million fund investing in Québec’s early-stage deep tech startups | In partnership with Centech, Boreal Ventures has launched as a new venture capital fund that aims to invest in Québec tech startups at the pre-seed and seed stages.
Boreal has secured $26 million CAD in initial investment capital from Cente... |
| 17.02.2021 | Boreal Ventures raises initial $26m to invest in deep tech | - |
| 04.01.2021 | The Biotech Paradox Of 2020: A Year In Review | 2020 was an incredibly paradoxical year for those of us in biotech: the striking dichotomy of simultaneously experiencing agonizing tragedy alongside buoyant optimism. |
| 16.11.2020 | Atlas Venture Adds Rajesh Devraj as Venture Partner | Atlas Venture, a Cambridge, Mass.-based early stage venture capital firm investing in biotech innovation, added Rajesh (Raj) Devraj, PhD, to a venture partner role.
Devraj will be working with the Atlas team to identify and execute upon com... |
| 28.10.2020 | PayPal invests $50m in eight black and Latinx-led venture funds | - |
| 07.06.2020 | Atlas Venture Raises $400 Million For Fund XII | Leading early-stage venture capital firm Atlas Venture announced that it closed its twelfth fund at $400 million
Leading early-stage venture capital firm Atlas Venture announced that it closed its twelfth fund at $400 million as part of a h... |
| 05.06.2020 | Atlas Venture Closes Fund XII, at $400M | Atlas Venture, a Cambridge, Mass.-based early stage venture capital firm investing in biotech innovation, closed its twelfth fund, at $400m.
Atlas Venture will continue to focus on building biotech companies to deliver high-impact therapies... |
| 05.06.2020 | Atlas Venture Announces $400 Million Fund XII | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, today announced the closing of its twelfth fund, raising $400 million in a highly oversubscribed fu... |
| 05.06.2020 | Atlas Venture : Announces $400 Million Fund XII and Expansion of Partnership | Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, today announced the closing of its twelfth fund, raising $400 million in a highly oversubscribed fundraise. With the closing of Fund X... |
| 09.03.2020 | Taiwan Life Insurance commits to invest $20m in two Lightspeed Venture funds | Premium
Taiwan Life Insurance Co.,Ltd, a Taiwanese leading insurance solution firm owned by Taiwanese financial group CTBC Financial Holding, has agreed to inject a total of $20 million in Lightspeed Venture Partners’ two private equity fun... |
| 02.01.2019 | Atlas Venture raises $250M for later-stage investments
W h i t e p a p e r
Vital Precision for Cost Reduction, QA, and Regulatory Compliance | Atlas Venture has raised $250 million to invest in existing portfolio companies. The fund, the first of its kind operated by Atlas, will enable the VC shop to support its startups through series B and beyond.
Sponsored by Agilent Technologi... |
| 02.01.2019 | As market shifts, Atlas Venture closes a $250 million fund to support its breakaway biotech bets | Atlas Venture, the Cambridge, Mass.-based early-stage, biotech-focused venture firm, has for the first time raised an opportunity fund designed to help it support its most promising, maturing portfolio companies.
The $250 million fund, anno... |
| 02.01.2019 | Atlas Venture Closes First Opportunity Fund, at $250M | Atlas Venture, a Cambridge, MA-based venture capital firm investing in biotech innovation, closed its first Opportunity Fund, at $250m.
With Atlas Venture Opportunity Fund I (AVOF I), the firm will invest in existing portfolio companies as ... |
| 02.01.2019 | Atlas Venture raises $250M for Opportunity Fund | The total amount raised represents a 25 percent increase over the $200 million that Atlas set out to raise when it opened the fund a little more than a month ago, according to a Nov. 29 Securities and Exchange Commission filing.
Unum Therap... |
| 27.09.2018 | Akrevia Therapeutics Launches with $30M Series A Financing Led by F-Prime Capital Partners and Atlas Venture | Akrevia Therapeutics, a privately-held biopharmaceutical company focused on developing highly-potent, tumor-targeted immuno-oncology therapeutics, today announced the closing of a $30 million Series A financing led by F-Prime Capital Partne... |
| 17.07.2018 | HotSpot Therapeutics Completes $45 Million Series A Financing | HotSpot Therapeutics, a new biotechnology company targeting nature's regulatory hotspots to discover and develop first-in-class medicines, today announced the completion of a $45 million Series A financing. "Regulatory hotspots" a... |
| 25.06.2018 | Akero Therapeutics Closes $65 Million Series A | Akero Therapeutics, Inc., a biotechnology company focused on transforming the treatment of non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases, today announced the completion of a $65 million Series A financing. The fi... |
| 30.04.2018 | Every Boston Venture Firm, Listed | The reports on 1Q 2018 are in: 1,683 venture-backed companies raised $28.2 billion in funds last quarter, according to industry database Pitchbook. It's the fourth quarter in a row that has seen over $20 billion in venture capital, and $28.... |
| 15.02.2018 | Meet Michael Yang, Managing Director at Comcast Ventures | Firm celebrates 20th anniversary and explores VR/AR and drones
As entrepreneurship has become a global meme, with the title of "Founder" worn like a badge of accomplishment, there's no shortage of emerging investors on hand to fun... |
| 30.10.2017 | Kymera Therapeutics Raises $30M In Series A | Kymera Therapeutics LLC today announced a $30M Series A Financing round to advance a transformational new therapeutic modality and discover breakthrough medicines for patients with previously untreatable diseases. The company is pioneering ... |
| 18.10.2017 | Gemini Therapeutics closes $42.5M Series A for dry age-related macular degeneration therapy | Atlas Venture, Lightstone Ventures and OrbiMed co-led the Series A, according to a news release. They also took part in the seed round last year.
James McLaughlin, Gemini Therapeutics cofounder and CEO, said that the company focuses on pati... |
| 29.06.2017 | Atlas Venture Announces $350 Million Fund XI | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, today announced the closing of its eleventh fund, raising $350 million in a highly oversubscribed f... |
| 29.06.2017 | Term Sheet — Thursday, June 29 | New Money, Old Deals, Lingering Questions
LA Tech: Upfront Ventures has closed its fourth core fund with $400 million in commitments. It’s the firm’s largest ever, and according to managing partner Mark Suster, the largest Los Angeles-based... |
| 01.06.2017 | Atlas Venture Adds Kevin Bitterman as a Partner | Atlas Venture, a Cambridge, MA-based early stage venture capital firm investing in promising biotech innovation, has hired Kevin Bitterman as a partner.
Kevin Bitterman, an experienced venture capitalist, will focus on creating and investin... |
| 01.06.2017 | Term Sheet — Thursday, June 1 | EXITS AND CONFLICTS
NYC Tech: Awhile back I had promised to provide updated deal data comparing exits for startups from NYC, LA and Boston. We can’t compare deal value of M&A exits since so many of the prices are not confirmed. For exam... |
| 16.11.2016 | Stem cell startup Magenta launches with $48.5m | In a company news release, Jason Gardner, CEO, president, and co-founder of Magenta Therapeutics said a new wave of stem cell science was ready for commercialization.
“Technical and scientific hurdles have relegated stem cell transplantatio... |
| 14.09.2016 | Sofinnova Partners and Atlas Venture Co-led $35 Million Series A for Delinia | CAMBRIDGE, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--Delinia, a new company developing novel therapeutics that rebalance the immune system to treat serious and life-threatening autoimmune diseases, announced today that it has closed a $35... |
| 07.09.2016 | Pharmacy disruptor PillPack has raised another $30.1M following expansion | The reality is that most older adults have at least one chronic condition and many have more, requiring them to take multiple medications. This population segment may also grapple with memory problems, making this streamlined approach to th... |
| 11.03.2016 | 4 factors that will jumpstart the Boston tech party revolution | Scott Maxwell Contributor
Scott Maxwell is the founder and senior managing partner at OpenView.
More posts by this contributor
The End Of The Startup Gold Rush, Absurd Burn Rates And Tourist VCs
Boston’s tech scene should shake off its infe... |
| 04.03.2016 | Daily funding roundup - March 4, 2016 | Snapchat bagged $175M funding; Oro received investment from Highland Europe; Wrap Media landed $4M
Snapchat raised another $175 million in venture funding. The funding came from Fidelity Investments, and it gives Snapchat a total of $1.34 b... |
| 18.02.2016 | Avrobio Raises Seed Funding | Avrobio, a Cambridge, MA and Toronto, ON-based clinical-stage biotechnology company developing transformative cell and gene therapies targeting cancer and rare diseases, raised a seed funding of undisclosed amount.
Atlas Venture of Cambridg... |
| 28.01.2016 | Here's How Often Boston VCs Actually Invest in Women Founders | Venture capital is taking it on the chin for fostering a boys' club culture. Women's share of the partnership at VC firms has actually declined over the past 15 years: The Diana Project at Babson counted 6 percent in 2014, down from 10 perc... |
| 01.09.2015 | Renaissance, MVCA Program Lures Half-Dozen Investors to Michigan | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Though Michigan’s startup community has experienced a ton of growth in the past 10 years, the state remains a place that is “underserved” when it comes to investment capital, ... |
| 28.05.2015 | Threat Stack Names Brian M. Ahern as New Chairman & CEO | Boston, MA – May 28, 2015 -- Threat Stack, Inc., the leader in continuous cloud security monitoring, today announced that its Board of Directors have appointed Brian M. Ahern as the company’s next Chairman and Chief Executive Officer, effec... |
| 17.04.2015 | Now 'Unshackled,' Atlas Venture Raises $280M for Biotech Deals | You might have recently caught wind of FKA, a Cambridge venture capital firm, whose letters stands for “Formerly Known as Atlas.” The firm includes the group of technology VCs that previously had been part of Atlas Venture until the firm sp... |
| 17.04.2015 | With new $280M fund, Atlas Venture cuts the IT and “right-sizes” to biotech | The new incarnation of Atlas just moved to 400 Technology Square in the life sciences-rich Kendall Park, also in Cambridge. Notably, Atlas just brought on a new chief financial officer- Ommer Chohan, former CFO of Summerhill Ventures in Tor... |
| 02.04.2015 | ZappRX raises $5.6M Series A as pharma becomes more responsive to specialty drug support needs | ZappRx will also work with obesity-focused biopharma company Zafgen (NASDAQ: ZFGN), to support patients with Prader-Willi syndrome — a genetic condition affecting up to 30,000 people — and hypothalamic injury-associated obesity.
Promoted
Th... |
| 02.04.2015 | ZappRx Raises $5.6 Million In Series A Funding To Expand The Company | Pharmacy coordination platform ZappRx announced it has raised $5.6 million in Series A funding today. The new financing will go to further build upon ZappRx’s prescription data automation technology and help to scale operations for the star... |
| 07.03.2015 | No one wants to buy from startups | I spend most days (and way too many nights and weekends) thinking about, evaluating, visiting, and coaching startups. It’s a never-ending series of pitches from people telling me they are about to take over the world to become the next Sale... |
| 07.03.2015 | No one wants to buy from startups | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
I spend most days (and way too many nights and we... |
| 24.02.2015 | Q4 Web Systems Secures $5M | Q4 Web Systems, a Toronto, Ontario, Canada-based provider of SaaS-based investor relations solutions for public companies, secured $5m in new financing.
The round was led by Plaza Ventures, with participation from Atlas Venture. In conjunct... |
| 11.02.2015 | Announcing The Judges For The TC Atlanta And Boston Pitch-Offs | One of the best parts of the TechCrunch Meetup Pitch-Offs, beyond the beer and the fun conversation and the new tech, is our amazing judges. The whole point of these events is to bring these regional communities together in the name of tech... |
